Form 4: Exelixis CEO Michael Morrissey Reports Stock Transactions
Insider Ownership Disclosure
Exelixis CEO Michael Morrissey disclosed tax-related share withholding and a transfer of shares to a family trust.
Summary
- CEO Michael Morrissey reported the withholding of 128,497 shares of common stock on May 15, 2026, to satisfy tax obligations related to the vesting of restricted stock units.
- On May 18, 2026, the CEO gifted 124,047 shares to the Morrissey Family Living Trust.
- Following these transactions, the CEO maintains a direct beneficial ownership of 1,362,008 shares and an indirect interest of 2,004,327 shares held by the family trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine tax and estate planning activities by the CEO.
Positives
- The CEO maintains a significant equity stake in the company, signaling long-term alignment with shareholder interests.
Negatives
- The transaction includes a reduction in direct holdings, though this is primarily attributed to tax withholding and estate planning.
Risks
- Reliance on equity-based compensation creates potential volatility in personal holdings based on stock price performance.
Future Outlook
No specific forward-looking guidance provided in this ownership disclosure.
Industry Context
StockSavvy.ai notes that executive stock transactions involving tax withholding and trust transfers are standard administrative procedures for leadership at large-cap biotechnology firms and generally do not reflect a change in operational outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 style tax withholding is consistent with standard executive compensation practices in the pharmaceutical industry.
- Transferring shares to a family trust is a common estate planning strategy among C-suite executives at companies like Amgen or Gilead Sciences.
Related Party Transactions
- Transfer of 124,047 shares to the Morrissey Family Living Trust, of which the reporting person is a trustee.
Stakeholder Impact
- Minimal impact on shareholders as the transactions represent internal rebalancing and tax compliance rather than a divestment of interest.
Next Steps
- Continued monitoring of executive equity holdings in future SEC filings.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Date of share withholding for tax obligations. |
| 05/18/2026 | Date of gift transfer to the Morrissey Family Living Trust. |
| 05/19/2026 | Filing date of the Form 4. |
Keywords
Exelixis, EXEL, Insider Trading, Form 4, Biotech, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.